211 related articles for article (PubMed ID: 23296123)
41. Combined E7-dendritic cell-based immunotherapy and human sodium/iodide symporter radioiodine gene therapy with monitoring of antitumor effects by bioluminescent imaging in a mouse model of uterine cervical cancer.
Jeon YH; Lee HW; Lee YL; Kim JE; Hwang MH; Jeong SY; Lee SW; Ahn BC; Ha JH; Lee J
Cancer Biother Radiopharm; 2011 Dec; 26(6):671-9. PubMed ID: 22091632
[TBL] [Abstract][Full Text] [Related]
42. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
[TBL] [Abstract][Full Text] [Related]
43. SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model.
Sharma RK; Srivastava AK; Yolcu ES; MacLeod KJ; Schabowsky RH; Madireddi S; Shirwan H
Vaccine; 2010 Aug; 28(36):5794-802. PubMed ID: 20603135
[TBL] [Abstract][Full Text] [Related]
44. Double demonstration of oncogenic high risk human papilloma virus DNA and HPV-E7 protein in oral cancers.
Pannone G; Santoro A; Carinci F; Bufo P; Papagerakis SM; Rubini C; Campisi G; Giovannelli L; Contaldo M; Serpico R; Mazzotta M; Lo Muzio L
Int J Immunopathol Pharmacol; 2011; 24(2 Suppl):95-101. PubMed ID: 21781453
[TBL] [Abstract][Full Text] [Related]
45. Comparison of HPV DNA vaccines employing intracellular targeting strategies.
Kim JW; Hung CF; Juang J; He L; Kim TW; Armstrong DK; Pai SI; Chen PJ; Lin CT; Boyd DA; Wu TC
Gene Ther; 2004 Jun; 11(12):1011-8. PubMed ID: 14985791
[TBL] [Abstract][Full Text] [Related]
46. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication.
Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH
BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937
[TBL] [Abstract][Full Text] [Related]
47. Development of an adenoviral vaccine against E6 and E7 oncoproteins to prevent growth of human papillomavirus-positive cancer.
Lee DW; Anderson ME; Wu S; Lee JH
Arch Otolaryngol Head Neck Surg; 2008 Dec; 134(12):1316-23. PubMed ID: 19075129
[TBL] [Abstract][Full Text] [Related]
48. Intrabodies targeting human papillomavirus 16 E6 and E7 oncoproteins for therapy of established HPV-associated tumors.
Paolini F; Amici C; Carosi M; Bonomo C; Di Bonito P; Venuti A; Accardi L
J Exp Clin Cancer Res; 2021 Jan; 40(1):37. PubMed ID: 33485370
[TBL] [Abstract][Full Text] [Related]
49. Enhanced therapeutic effects conferred by an experimental DNA vaccine targeting human papillomavirus-induced tumors.
Diniz MO; Cariri FA; Aps LR; Ferreira LC
Hum Gene Ther; 2013 Oct; 24(10):861-70. PubMed ID: 24007495
[TBL] [Abstract][Full Text] [Related]
50. Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases.
Skeate JG; Woodham AW; Einstein MH; Da Silva DM; Kast WM
Hum Vaccin Immunother; 2016 Jun; 12(6):1418-29. PubMed ID: 26835746
[TBL] [Abstract][Full Text] [Related]
51. Different domains of glycoprotein 96 influence HPV16 E7 DNA vaccine potency via electroporation mediated delivery in tumor mice model.
Daemi A; Bolhassani A; Rafati S; Zahedifard F; Hosseinzadeh S; Doustdari F
Immunol Lett; 2012 Dec; 148(2):117-25. PubMed ID: 23085605
[TBL] [Abstract][Full Text] [Related]
52. TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers.
Barrios K; Celis E
Cancer Immunol Immunother; 2012 Aug; 61(8):1307-17. PubMed ID: 22527249
[TBL] [Abstract][Full Text] [Related]
53. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck.
Albers A; Abe K; Hunt J; Wang J; Lopez-Albaitero A; Schaefer C; Gooding W; Whiteside TL; Ferrone S; DeLeo A; Ferris RL
Cancer Res; 2005 Dec; 65(23):11146-55. PubMed ID: 16322265
[TBL] [Abstract][Full Text] [Related]
54. Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts.
Tseng CW; Trimble C; Zeng Q; Monie A; Alvarez RD; Huh WK; Hoory T; Wang MC; Hung CF; Wu TC
Cancer Immunol Immunother; 2009 May; 58(5):737-48. PubMed ID: 18815785
[TBL] [Abstract][Full Text] [Related]
55. Zinc finger nucleases targeting the human papillomavirus E7 oncogene induce E7 disruption and a transformed phenotype in HPV16/18-positive cervical cancer cells.
Ding W; Hu Z; Zhu D; Jiang X; Yu L; Wang X; Zhang C; Wang L; Ji T; Li K; He D; Xia X; Liu D; Zhou J; Ma D; Wang H
Clin Cancer Res; 2014 Dec; 20(24):6495-503. PubMed ID: 25336692
[TBL] [Abstract][Full Text] [Related]
56. Exploiting the plant secretory pathway to improve the anticancer activity of a plant-derived HPV16 E7 vaccine.
Franconi R; Massa S; Illiano E; Mullar A; Cirilli A; Accardi L; Di Bonito P; Giorgi C; Venuti A
Int J Immunopathol Pharmacol; 2006; 19(1):187-97. PubMed ID: 16569357
[TBL] [Abstract][Full Text] [Related]
57. Single-dose, therapeutic vaccination of mice with vesicular stomatitis virus expressing human papillomavirus type 16 E7 protein.
Liao JB; Publicover J; Rose JK; DiMaio D
Clin Vaccine Immunol; 2008 May; 15(5):817-24. PubMed ID: 18337377
[TBL] [Abstract][Full Text] [Related]
58. Different spectra of therapeutic vaccine development against HPV infections.
Bolhassani A; Mohit E; Rafati S
Hum Vaccin; 2009 Oct; 5(10):671-89. PubMed ID: 19684468
[TBL] [Abstract][Full Text] [Related]
59. Persistence of high-grade cervical dysplasia and cervical cancer requires the continuous expression of the human papillomavirus type 16 E7 oncogene.
Jabbar SF; Abrams L; Glick A; Lambert PF
Cancer Res; 2009 May; 69(10):4407-14. PubMed ID: 19435895
[TBL] [Abstract][Full Text] [Related]
60. Engineered outer membrane vesicle is potent to elicit HPV16E7-specific cellular immunity in a mouse model of TC-1 graft tumor.
Wang S; Huang W; Li K; Yao Y; Yang X; Bai H; Sun W; Liu C; Ma Y
Int J Nanomedicine; 2017; 12():6813-6825. PubMed ID: 28979120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]